The landscape of blockbuster medicines has been changing over the last years from small molecule drugs to biologicals. Although small molecule drugs still dominate the global pharmaceutical market in terms of numbers, biologicals are catching up. In fact, they make up seven of the top 10 best-selling medicines. The high, and increasing, cost of biologicals, however, is a strain for healthcare budgets. Fortunately, as more patents on originator biologicals expire, biosimilars are expected to take an increasing share of the biologicals market. In light of these facts, this paper presents an update of estimated patent/exclusivity expiry dates for some of the best-selling biologicals.
Subscribe now to GaBI Journal to view full information of this article to be published in the next journal issue.